Compare GDOT & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDOT | NVCT |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.0M | 617.7M |
| IPO Year | 2010 | 2021 |
| Metric | GDOT | NVCT |
|---|---|---|
| Price | $13.32 | $23.95 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.00 | $10.00 |
| AVG Volume (30 Days) | ★ 287.2K | 173.5K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $2,080,491,000.00 | N/A |
| Revenue This Year | $11.07 | N/A |
| Revenue Next Year | $5.69 | N/A |
| P/E Ratio | $39.42 | ★ N/A |
| Revenue Growth | ★ 20.69 | N/A |
| 52 Week Low | $10.10 | $5.55 |
| 52 Week High | $15.41 | $29.28 |
| Indicator | GDOT | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 50.63 |
| Support Level | $12.98 | $17.98 |
| Resistance Level | $13.70 | $23.12 |
| Average True Range (ATR) | 0.19 | 1.53 |
| MACD | -0.03 | -0.25 |
| Stochastic Oscillator | 30.30 | 12.21 |
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for todays workforce.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.